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INTRODUCTION
Cardiovascular impairment after weaning from car-
diopulmonary bypass （CPB） is a major concern in car-
diac surgery. To improve the cardiac status after CPB, 
anesthetic management in cardiac surgery is per-
formed using Catecholamine, phosphodiesterase inhibi-
tor and coronary dilator. Administration of these drugs 
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SUMMARY
Objective：Landiolol is a new ultra-short acting beta-adrenergic blocker that has potential for use in pe-
rioperative hemodynamic stabilization. The purpose of this study was to examine the effect of combined ad-
ministration of landiolol and Catecholamine on regulation of heart rate in tachycardia after cardiopulmonary 
bypass.
Design：The study was performed as a prospective controlled trial.
Setting：A university hospital.
Participants：The subjects were 30 of 64 patients with heart rate ≥ 115 bpm after weaning from cardio-
pulmonary bypass.
Interventions：Fifteen of the patients （the landiolol group） were administered landiolol at a dose of 
3-5 mg/kg/min without a decrease in the dose of Catecholamine. The other 15 patients （the control group） 
did not receive landiolol, but the Catecholamine dose of 1 mg/kg/min was decreased to reduce the heart 
rate.
Results：Mean arterial pressure, cardiac index and heart rate were measured 5, 10 and 15 min after drug 
administration and postoperatively. Mean arterial pressure and cardiac index were unchanged after drug 
administration, but heart rate was significantly lower after 15 min and postoperatively in patients adminis-
tered landiolol compared with those who did not receive landiolol.
Conclusions：Combined administration of landiolol and Catecholamine is useful for stabilization of cardio-
vascular changes after cardiopulmonary bypass surgery.
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Sampling procedure
No premedication was given in any cases. An elec-
trocardiogram （ECG） was recorded and non-invasive 
blood pressure was measured before induction of anes-
thesia. Oxygen saturation was monitored continuously 
by pulse oximetry （DynascopeTM, Fukuda Denshi, To-
kyo） and arterial blood pressure was measured contin-
uously at the left radial artery using a tonometric 
blood pressure monitor （DynascopeTM）. General anes-
thesia was induced with fentanyl （4 mg/kg）, midazo-
lam （0.5 mg/kg） and vecuronium （0.1 mg/kg）. After 
tracheal intubation, a Swan-Ganz catheter was insert-
ed into the right internal jugular vein for monitoring 
of cardiac output as the cardiac index （CI） with a vol-
umetric monitor （Vigilance, Edwards Lifesciences, Ir-
vine, CA, USA）. Anesthesia was maintained with air-
oxygen-sevo f lurane inha la t i on  （ 1 - 3％） and 
intermittent bolus injection of fentanyl and midazolam. 
During CPB, patients were given fentanyl （200 mg/h）, 
midazolam （2 mg/h） and pancuronium （2 mg/h）. 
Continuous administration of dopamine and dobu-
tamine was started before weaning from CPB in all pa-
tients. The dosage of Catecholamine was determined 
based on the preoperative cardiac condition of each 
patient. Noradrenaline was administered continuously 
to some patients as required. In patients with heart 
rate ≥ 115 bpm after weaning from CPB, those as-
signed to the landiolol group were administered landi-
olol at a dose of 3-5 mg/kg/min without a decrease of 
Catecholamine. Those in the control group were not 
administered landiolol, but the dose of Catecholamine 
was decreased to 1 mg/kg/min to reduce the heart 
rate. Heart rate and blood pressure were measured 3 
times every five minutes after the start of heart rate 
regulation and at the completion of surgery, and CI 
was determined before and after heart rate regulation. 
Bradycardia （ £ 50 bpm）, hypotension （systolic blood 
pressure £ 80 mmHg） and low cardiac output（CI £  
2 .2 L/min/m2） were monitored as potential adverse 
events.
Statistical analysis
Data are expressed as means±SD. The difference in 
the dosage of Catecholamine between the control and 
landiolol groups was analyzed using Bonferroni test. 
Other data were analyzed by one-way ANOVA and 
requires precise management to moderate hemody-
namic fluctuations in the perioperative period. Howev-
er, there are differences among individuals in terms of 
responsiveness to Catecholamine and phosphodi-
esterase inhibitor, and these differences may cause 
tachyarrhythmia after weaning from CPB. Tachyar-
rhythmia also increases myocardial ischemia due to in-
creased myocardial oxygen consumption, enhancing 
the incidence of perioperative ischemic heart diseases 
and heart failure.
Several recent reports have described the efficacy of 
beta blockers for hemodynamic stabilization and pro-
tection against myocardial ischemic dysfunction1）. Lan-
diolol （ONOACT, Ono pharmaceutical company, Osa-
ka, Japan）, a ultra-short acting beta adrenergic 
blocker, is particularly useful for perioperative hemo-
dynamic stabilization2, 3）. However, the hemodynamic 
effects of combined administration of landiolol and Cat-
echolamine for cardiovascular control during cardiac 
surgery have not been examined. In the current study, 
patients were continuously administered a low dose of 
landiolol to prevent tachycardia after weaning from 
CPB. The resulting decrease in heart rate suggests 
that landiolol is useful for maintenance of a stable 
heart rate under these conditions.
PATIENTS AND METHODS
Patients
This study protocol was approved by Dokkyo Uni-
versity Hospital Ethics Committee and written in-
formed consent was obtained from all patients before 
the start of the study. The patients were allocated ran-
domly to control and landiolol groups in equal numbers 
using randomly selected, mixed, sealed, opaque enve-
lopes. The subjects were restricted to patients with 
heart rate ≥ 115 bpm after weaning from CPB. To 
avoid serious adverse effects including arrhythmia, hy-
potension and low cardiac output syndrome that may 
be induced by bradycardia and abnormal atrioventric-
ular conduction, the exclusion criteria were a history 
of serious arrhythmia except sinus tachycardia and su-
praventricular tachycardia, and a cardiac index （CI） 
£ 2.2 L/min/m2 （the lower limit of the normal range） 
at the start of drug administration.
28 DJMS
Landiolol and Catecholamine after CPB
olol and control groups. In the landiolol group, 10 pa-
tients underwent coronary artery bypass grafting 
（CABG） and 5 underwent aortic valve replacement 
（AVR）. In the control group, 10 underwent CABG, 4 
underwent AVR, and one patient had mitral valve re-
placement （MVR）. The time of extracorporeal circula-
tion was 171±63 min in the landiolol group and 161±
39 min in the control group, with no significant differ-
ence between the groups.
The amounts of dopamine, dobutamine and nora-
drenaline administered to patients in both groups and 
the dose of landiolol given to patients in the landiolol 
group are shown in Table 2. The initial doses of dop-
amine and dobutamine were higher in the control 
group compared to the landiolol group, but with no 
significant difference between the groups. However, 
intergroup comparison was performed by Mann-Whit-
ney U test. Values of P＜0.05 were considered statisti-
cally significant.
RESULTS
We obtained informed consent from 64 patients who 
underwent cardiac surgery during the study period, 
and of which 30 patients （22 men and 8 women；age, 
49-79 years old；height, 145-173 cm；weight, 39-
76 kg）, were selected as subjects in this study. Their 
heart rates were over 115 bpm after weaning from 
CPB and they were not included in our exclusion crite-
ria.
The demographic characteristics of the 30 patients 
are presented in Table 1 . There were no significant 
differences in age, height or weight between the landi-
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Table 1　Demographic characteristics of the patients （1）
Landiolol
Control
（catecholamine adjusted）
Number of subjects N＝11 N＝11
Gender（M：F） 7：4 9：2
Age（years） 62±9.8 65±7.7
Height（cm） 159±9.8 159±7.9
Weight（kg） 61±9.9 57±12
Surgical method CABG：8AVR：3 CABG：7AVR：3MVR：1
Cardiopulmonary bypass 
time（minutes）
171±66 153±28
Data are shown as mean±SD except for gender and surgical method.
M＝male；F＝female；CABG＝coronary artery bypass grafting surgery；AVR＝
aortic valve replacement；MVR＝mitral valve replacement.
Table 2　Demographic characteristics of the patients （2）
Landiolol
Control
（catecholamine adjusted）
DOA（g） 4.3±1.3 3.6±1.6
DOB（g） 4.6±1.2 4.1±2.5
Number of subjects 
treated with NA
6 4
NA（g） 0.04±0.08 0.02±0.03
Landiolol 5g：10 ／ 3g：1 0
Landiolol（g） 4.8±0.6 0
Data are shown as the mean±SD, except for the number of subjects 
treated with noradrenaline.
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Changes in heart rate and blood pressure deter-
mined every five minutes after the start of heart rate 
regulation and at the completion of surgery are shown 
in Figures 1 and 2 , respectively. Changes in CI are 
shown in Figure 3 . Heart rate （Figure 1） showed a 
the doses of dopamine and dobutamine used to regu-
late heart rate were significantly lower in the control 
group compared to the landiolol group. There was no 
difference in the noradrenaline dose between the two 
groups.
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Landiolol Group
Control Group (Catecholamine adjusted)
※：p＜0.05
Before 5 min 10 min 15 min          Completion 
of surgery
Fig1. Changes in Heart Rate
HR
(bpm)
Figure 1　Changes in heart rate
Values are shown as means±SD. Before＝before control of heart rate；5 min, 10 
min and 15 min＝5 min, 10 min and 15 min after hemodynamic stabilization with 
landiolol administration or Catecholamine adjustment. MBP＝mean blood 
pressure.
※ p＜0.05；landiolol group vs. control group.
BP
(mmHg)
Landiolol Group
Control Group (Catecholamine adjusted)
Before 5 min 10 min 15 min          Completion 
of surgery
Fig 2. Changes in Blood Pressure
Figure 2　Changes in blood pressure
Values are shown as means±SD. Before＝before control of heart rate；5 min, 10 min 
and 15 min＝5 min, 10 min and 15 min after hemodynamic stabilization with landiolol 
administration or Catecholamine adjustment.
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culation are more of a concern as a factor causing 
tachycardia after weaning from CPB. Catecholamine is 
useful for improving cardiac contraction, but common 
Catecholamine such as dopamine and dobutamine can 
induce perioperative tachyarrhythmia, rather than 
prompt pharmacological regulation of heart rate. Ad-
ministration of a combination of dopamine and dobu-
tamine in equal amounts or with a higher proportion 
of dobutamine has been shown to be effective in en-
hancing right ventricular performance 4）. However, 
Mayr et al. have proposed that the severity of cardio-
vascular dysfunction with tachyarrhythmia has a 
strong causal relationship with Catecholamine thera-
py5）. Administration of these agents in weaning from 
CPB induces fluctuations in heart rate that are often 
difficult to regulate, and increased cardiac performance 
due to Catecholamine administration may induce intra-
operative myocardial ischemia. Therefore, regulation of 
heart rate is required in weaning from CPB.
Landiolol is a recently developed beta-adrenergic 
receptor antagonist that can act as an antichronotropic 
agent. Landiolol has a greater specific beta-1 selectivi-
ty （beta-1/beta-2＝277） and a shorter elimination 
half-life （4 min in healthy subjects） than esmolol, and 
has been used to treat tachyarrhythmia safely 6）, in-
cluding sinus tachycardia, tachycardiac atrial fibrilla-
tendency to decrease from 5 min after the start of lan-
diolol administration, but remained at around 110-
120 bpm in the control group. At 15 min after the start 
of drug administration and at the completion of sur-
gery, heart rate was significantly lower in the landiolol 
group （90-100 bpm） compared with the control group 
（※ p＜0.05 VS control group）. In contrast, there were 
no significant differences in blood pressure （Figure 2） 
and CI （Figure 3） between the groups throughout the 
study.
No adverse reactions of bradycardia （£ 50 bpm）, hy-
potension （systolic blood pressure £ 80 mmHg） or low 
cardiac output（CI £ 2.2 L/min/m2） were observed in 
the study.
DISCUSSION
Tachycardia after weaning from CPB may be caused 
by a reduction in circulating blood volume, physical 
stimulus of the heart by surgical procedures, adventi-
tious cardiogenic arrhythmia, or an adverse reaction to 
Catecholamines. The reduction in circulating blood vol-
ume can be treated by increasing fluid infusion and 
blood transfusion, and adventitious cardiogenic ar-
rhythmia can be resolved by administration of appro-
priate antiarrhythmic agents. However, adverse effects 
of catechol amines administered to support cardiac cir-
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CI
(L/kg/min2)
2.2
Before HR control After HR Control
Landiolol Group
Control Group (Catecholamine adjusted)
Fig 3. Changes in cardiac index (CI)
Figure 3　Changes in cardiac index
Values are shown are means±SD. Before HR control＝before control of heart rate 
with landiolol administration or Catecholamine adjustment；After HR control＝after 
completion of surgery in both groups. CI＝cardiac index.
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from CPB. In a future study, it will be necessary to ex-
amine the effect of esmolol and other beta 1 blockers 
on the regulation of heart rate after weaning from 
CPB in cardiac surgery.
Common Catecholamine, such as dopamine or dobu-
tamine, is usually initially administered at 3-5 mg/kg/
min or less for weaning from CPB. And, Catecholamine 
administration should be decreased when there is a 
risk of inducing of excessive cardiac function. There-
fore, we decreased the dosage of both Catecholamines 
to 1 mg/kg/min to avoid deterioration of cardiac func-
tion in the absence of use of landiolol. However, we 
conclude that combined continuous administration of 
landiolol at 3-5 mg/kg/min with no reduction in both 
Catecholamines can decrease heart rate without reduc-
ing blood pressure and CI significantly. Therefore, this 
protocol can be used to stabilize cardiovascular reac-
tions after cardiopulmonary bypass in cardiac surgery.
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